11 withdrawn. 11 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Withdrawn 11 |
| Phase 2 | 2 | Withdrawn 2 |
Follow Leukemia, Lymphoid: new trials by email Literature Review of Leukemia, Lymphoid trials Research Report on Leukemia, Lymphoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies Liso-cel, Idelalisib, Rituximab - Leukemia, Lymphocytic, Chronic, B-Cell | Phase 3 | Withdrawn | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2024-01-16 | 2024-04-02 | |
| Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia Tisagenlecleucel, Blinatumomab, Inotuzumab - Acute Lymphoblastic Leukemia | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2020-06-05 | 2020-07-09 | |
| Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT Atorvastatin, Methotrexate, Tacrolimus - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 3 | Withdrawn | Loyola University | 2019-12-10 | 2021-04-27 | |
| CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Cerdulatinib - Peripheral T-Cell Lymphoma (PTCL NOS), Nodal Lymphomas of T Follicular Helper (TFH) | Phase 2 / Phase 3 | Withdrawn | Portola Pharmaceuticals | 2019-11-15 | 2023-02-21 | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) Duvelisib, Placebo, Rituximab - Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma | Phase 3 | Withdrawn | SecuraBio | 2015-12-01 | 2021-03-17 | |
| Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia insulin glargine recombinant, therapeutic insulin - Hyperglycemia, Leukemia | Phase 3 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2009-05-01 | 2013-08-30 | |
| Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma rituximab, fludarabine phosphate, pixantrone dimaleate - Leukemia, Lymphoma | Phase 3 | Withdrawn | CTI BioPharma | 2007-08-01 | 2020-10-19 | |
| Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL Dasatinib - Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Withdrawn | Bristol-Myers Squibb | 2006-12-01 | 2016-02-17 | |
| This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL) Genasense® (, oblimersen sodium G3139) - Lymphocytic Leukemia | Phase 3 | Withdrawn | Genta Incorporated | 2006-06-01 | 2008-02-11 | |
| Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia asparaginase, cyclophosphamide, cytarabine - Leukemia | Phase 3 | Withdrawn | National Institutes of Health Clinical Center (CC) | 1999-10-01 | 2012-03-23 | |
| Bone Marrow Transplantation in Treating Patients With Leukemia anti-thymocyte globulin, cyclophosphamide, cyclosporine - Graft Versus Host Disease, Leukemia | Phase 3 | Withdrawn | Masonic Cancer Center, University of Minnesota | 1996-04-01 | 2020-01-03 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Leukemia (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Myeloid, Acute (3) · Graft vs Host Disease (2) · Lymphoma (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Non-Hodgkin (2) · Bronchiolitis Obliterans Syndrome (1) · Congenital Abnormalities (1) · Hyperglycemia (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)
Hematologic Diseases (11) · Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Lymphatic Diseases (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Leukemia (7) · Chronic Disease (5) · Disease Attributes (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Leukemia, Myeloid (4)
Cyclophosphamide (3) · Methotrexate (3) · Rituximab (3) · Bendamustine Hydrochloride (2) · Radiotherapy (2) · fludarabine phosphate (2) · 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide (1) · Antilymphocyte Serum (1) · Asparaginase (1) · Atorvastatin (1) · Cyclosporine (1) · Cytarabine (1) · Dasatinib (1) · Daunorubicin (1) · Hydrocortisone (1)
Bristol-Myers Squibb (1) · CTI BioPharma (1) · Genta Incorporated (1) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (1) · Loyola University (1) · Masonic Cancer Center, University of Minnesota (1) · National Institutes of Health Clinical Center (CC) (1) · Novartis Pharmaceuticals (1) · Portola Pharmaceuticals (1) · SecuraBio (1) · University of Medicine and Dentistry of New Jersey (1)
United States (7) · Italy (2) · Netherlands (2) · United Kingdom (2) · Austria (1) · Belgium (1) · France (1) · Germany (1) · Hungary (1) · India (1) · Norway (1) · Poland (1) · Russia (1) · Spain (1) · Sweden (1)
Hagop Youssoufian, MD (1) · Ian Trevor Magrath, MD, FRCP, FRCPath (1) · Igor Gorbatchevsky, MD (1) · John E. Wagner, MD (1) · Mecide Gharibo, MD (1) · Patrick Stiff, MD (1)
P30CA072720 (1)